Home
>
US Stocks
>
Compugen Ltd
Compugen Ltd
CGEN

Compugen Ltd (CGEN)

$6.261.73%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
$6.17
Today Low/High
$5.95 / $6.31
52 Week Low/High
$5.88 / $19.9
P/E ratio
-14.4224
Market Cap
$515.26M

Company Details

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is expected to enter the clinic in early 2020. The Company's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA.
Organisation
Compugen Ltd
Employees
45
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Compugen Ltd (CGEN) share price today?

Can Indians buy Compugen Ltd (CGEN) shares?

How can I buy Compugen Ltd (CGEN) shares from India?

Can Fractional shares of Compugen Ltd (CGEN) be purchased?

What are the documents required to start investing in Compugen Ltd (CGEN) stocks?

We are a SEBI registered investement advisor